Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Genetics and epigenetics, Biochemistry and molecular biology, Laboratory management, Profession, Oncology, Omics

Lessons Learned, with Pier Paolo Pandolfi

At a Glance

  • Career changes are possible at any stage – so it’s important to follow your inclinations
  • Don’t be afraid to question the standard protocols or opinions in your field
  • No one can excel at everything, but wise choices mean everyone can excel at something
  • Rewards and honors are wonderful motivation – but don’t forget that they belong to the team

Don’t be afraid to make a U-turn toward your true calling

My first major was actually philosophy. In Europe, you have to choose either medicine or philosophy, so I chose the latter. My family were all in humanities. I really loved philosophy – and still do – but, during my studies, I realized the topics that stuck out to me were based in the core of scientific reasoning: epistemology, philosophy of science, logic, you name it. So, I asked myself: Do I just want to discuss science, or do I want to become a scientist?

Because of my late switch to medicine, I was quite old when I finally graduated. Luckily, the speed at which my early career was propelled made up for it. During my final year of study in medicine, we ended up cloning the translocation associated with acute promyelocytic leukemia (APL). That discovery was transformative for me, the research group, and patients – but it was just the first step; in the following years, we were able to model the disease in mice. It’s because of this work that I was later recruited by Memorial Sloan Kettering Cancer Center in New York to run my own lab. While there, my colleagues and I completed the bench-to-bedside cycle by testing drug combinations that might cure APL. A derivative of vitamin A (ATRA) plus arsenic trioxide, or ATRA plus histone deacetylase inhibitors, proved effective and curative.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine
Register

Or Login as a Guest or via Social Media

About the Author

Pier Paolo Pandolfi

Pier Paolo Pandolfi is Director of Cancer Research Institute and George C. Reisman Professor of Medicine and Pathology at Harvard Medical School.

Newsletter

Send me the latest from The Pathologist.

Sign up now

Related Articles

Diagnostics

The Evolution of Epigenetic Biomarkers

| Niamh Buckley, Laura Feeney, James Beirne, and Paul Mullan

Subspecialties

A Lasting Legacy

| Mary J. Wirth

Diagnostics

Thinking Outside the (Genome) Box

| Jason Mellad

Most Popular

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register